You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

molecular remission

Showing 26 - 50 of 8,221
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Lymphoblastic Leukemia Trial in New York (Ruxolitinib, Dasatinib, Dexamethasone)

Active, not recruiting
  • Acute Lymphoblastic Leukemia
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 25, 2022

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Trial in Tianjin (Olverembatinib, Venetoclax, prednisone)

Recruiting
  • Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Oct 21, 2022

B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia Trial (Azacitidine Injection,

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • +2 more
  • Azacitidine Injection
  • +2 more
  • (no location specified)
Oct 15, 2023

ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse, Acute Lymphocytic Leukemia Refractory Trial (Tafasitamab)

Not yet recruiting
  • ALL, Childhood B-Cell
  • +2 more
  • Tafasitamab
  • (no location specified)
Nov 25, 2022

B Acute Lymphoblastic Leukemia Trial in London (PBLTT52CAR19)

Recruiting
  • B Acute Lymphoblastic Leukemia
  • London, United Kingdom
    Great Ormond Street Hospital
Dec 15, 2021

Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma Trial in Frankfurt (Main) (Rituximab, Nelarabine, PEG-Asparaginase)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Lymphoblastic Lymphoma
  • Frankfurt (Main), Germany
    University Hospital of Frankfurt (Main)
Jul 1, 2022

Triple-negative Breast Cancer Trial in Shanghai (A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab, B1: TROP2 ADC)

Not yet recruiting
  • Triple-negative Breast Cancer
  • A1: SHR-A1811
  • +11 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 19, 2023

Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse Trial in Italy (Ponatinib)

Recruiting
  • Philadelphia-Positive ALL
  • Acute Lymphoblastic Leukemia, in Relapse
  • Ancona, Italy
  • +21 more
Jan 3, 2022

3TR Systemic Lupus Erythematosus Study Protocol 2

Not yet recruiting
  • Systemic Lupus Erythematosus (SLE)
  • Blood sample
  • +4 more
  • (no location specified)
Feb 17, 2023

Acute Lymphoid Leukemia, Acute Lymphoblastic Leukemia Trial in Aurora (CD19 Directed CAR T Cell)

Not yet recruiting
  • Acute Lymphoid Leukemia
  • Acute Lymphoblastic Leukemia
  • CD19 Directed CAR T Cell
  • Aurora, Colorado
    University of Colorado Hospital
Sep 12, 2022

Philadelphia-Positive ALL Trial in Suzhou (Olverembatinib combined with chemo)

Not yet recruiting
  • Philadelphia-Positive ALL
  • Olverembatinib combined with chemotherapy
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University, Jiangsu Ins
Jul 17, 2022

Systemic Lupus Erythematosus (SLE) Trial (Blood sample, Urine sample, Saliva sample)

Not yet recruiting
  • Systemic Lupus Erythematosus (SLE)
  • Blood sample
  • +4 more
  • (no location specified)
Jul 12, 2022

Acute Lymphoblastic Leukemia Trial in Ann Arbor (Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Nov 28, 2022

Crohn Disease, Ulcerative Colitis Trial (Adalimumab-680LT, Control)

Not yet recruiting
  • Crohn Disease
  • Ulcerative Colitis
  • (no location specified)
Oct 30, 2023

TNBC - Triple-Negative Breast Cancer Trial (A1:SG with SHR3680, A2:SG, B1:SG with SHR1210)

Not yet recruiting
  • TNBC - Triple-Negative Breast Cancer
  • A1:SG with SHR3680
  • +7 more
  • (no location specified)
Jun 23, 2023

Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated

Completed
  • Chronic Myeloid Leukaemia
  • Rionero in Vulture, Potenza, Italy
  • +32 more
Oct 24, 2022

NK-T-Cell Lymphoma, Extranodal Trial (Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
  • (no location specified)
Mar 7, 2023

Acute Lymphoblastic Leukemia, Adult, Ph+ ALL, Newly Diagnosed Trial in Czechia (Ponatinib 15 MG Oral Tablet)

Active, not recruiting
  • Acute Lymphoblastic Leukemia, Adult
  • +2 more
  • Ponatinib 15 MG Oral Tablet
  • Brno, Czechia
  • +6 more
Nov 30, 2022

Relapsed/Refractory Philadelphia Positive B-precursor ALL Trial in Worldwide (Blinatumomab)

Completed
Has Results
  • Relapsed/Refractory Philadelphia Positive B-precursor ALL
  • Duarte, California
  • +21 more
Sep 8, 2022

Optimization of Psoriatic and Seronegative Rheumatoid Arthritis

Recruiting
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Phenotyping of synovial immune and stromal cells
  • Rome, Italy
  • +1 more
Mar 2, 2023

Chronic Phase Chronic Myeloid Leukemia Trial in Worldwide (Dasatinib)

Completed
Has Results
  • Chronic Phase Chronic Myeloid Leukemia
  • Duarte, California
  • +27 more
Dec 7, 2021

T-Cell Large Granular Lymphocyte Leukemia Trial in Columbus (Oral Azacitidine)

Recruiting
  • T-Cell Large Granular Lymphocyte Leukemia
  • Oral Azacitidine
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 18, 2022

Chronic Myeloid Leukemia, BCR/ABL-Positive Trial in Taipei

Not yet recruiting
  • Chronic Myeloid Leukemia, BCR/ABL-Positive
    • Taipei, Taiwan
      National Taiwan University Hospital
    Jul 24, 2022

    Tyrosine Kinase Inhibitors, Chronic Myeloid Leukemia Trial in Poitiers (treatment of TKI in CML)

    Not yet recruiting
    • Tyrosine Kinase Inhibitors
    • Chronic Myeloid Leukemia
    • treatment of TKI in CML
    • Poitiers, France
      Chu Poitiers
    Feb 21, 2023

    Amyloidosis, Primary, Cardiomyopathy Trial in Boston (F-18 florbetapir/C-11 acetate PET, MRI, N-13 ammonia PET)

    Recruiting
    • Amyloidosis, Primary
    • Cardiomyopathy
    • F-18 florbetapir/C-11 acetate PET
    • +2 more
    • Boston, Massachusetts
      Brigham and Womens' Hospital
    Oct 23, 2022